Daftary GS, et al. - Researchers sought to determine how pregnancy outcomes are correlated to oocyte number resulting from stimulation with highly-purified human menopausal gonadotropin (HP-hMG) or recombinant follicle stimulating hormone (rFSH) in fresh and frozen cycles. In this multicenter, randomized, assessor-blind, non-inferiority study, they performed randomization 1:1 of ovulatory women aged 21-35 years with body mass index 18-30 kg/m² and serum AMH ≥ 5 ng/mL to a 150 IU starting dose of HP-hMG (n=311) or rFSH (n=309). Patients predicted to be high-responders showed no benefit in terms of the cumulative live birth rate with supernumerary oocytes; moreover, these may have contributed to the increase in observed adverse events. In fresh transfer cycles, they noted a negative impact of retrieval of high numbers of oocytes (>15) on the ongoing pregnancy rate with only a marginal benefit to cumulative live birth rates. The data thereby suggest that optimal fresh and cumulative efficacy and safety outcomes can be obtained by retrieval of 8-14 oocytes through proper selection of gonadotropin type and dose.